Vomiren 0.5mg Tablet

Uses of Vomiren 0.5mg Tablet

• Chemotherapy-induced nausea and vomiting
• Post-operative nausea and vomiting

How does Vomiren 0.5mg Tablet work?

 Vomiren 0.5mg Tablet blocks the action of certain natural substances that can trigger nausea and vomiting.

Side Effects of Vomiren 0.5mg Tablet

• Headache
• Difficulty with bowel movements
• Dry mouth
• Chills
• Blurred vision
• Difficulty in breathing
• Chest discomfort

Quick Suggestions:

• Carefully follow all the instructions given by your doctor and take/use Palonosetron exactly as directed.
• This medicine is not recommended for use in patients below 18 years of age
• Take palonosetron as directed, usually one hour before chemotherapy or surgery, unless otherwise instructed by your doctor
• Alcohol and some medications may interact with palonosetron, potentially affecting its effectiveness or causing unwanted side effects. Inform your doctor about all the medications, supplements, and herbal products you are taking to ensure there are no potential interactions
• Nausea and vomiting can lead to dehydration, so it's essential to drink plenty of fluids, especially after chemotherapy or surgery
• Let your doctor know if you are pregnant planning for pregnancy or breastfeeding
• Report any unusual symptoms to the doctor immediately.

Indication of Vomiren 0.5mg Tablet

Palonosetron is used to control nausea and vomiting that occurs as a result of chemotherapy (treatment of cancer) and is also used for Postoperative nausea and vomiting following surgery in adults.

Pharmacology

Chemotherapeutic agents can induce nausea and vomiting by triggering the release of serotonin (5-HT) from enterochromaffin cells in the small intestine. This released serotonin then activates 5-HT3 receptors located on vagal afferents, initiating the vomiting reflex. Similarly, postoperative nausea and vomiting can result from various factors related to the patient, surgery, and anesthesia, leading to the release of serotonin (5-HT) and subsequent activation of neuronal pathways in both the central nervous system and the gastrointestinal tract.

The 5-HT3 receptor plays a crucial role in mediating these emetic responses. Vomiren 0.5 mg acts as a 5-HT3 receptor antagonist, meaning it competes with serotonin for binding to these receptors. By binding strongly to the 5-HT3 receptor and having little or no affinity for other receptors, Vomiren 0.5 mg effectively inhibits the binding of serotonin to these receptors. This inhibition prevents the activation of the vomiting reflex, thereby reducing or preventing nausea and vomiting.

Dosage & Administration of Vomiren 0.5mg Tablet

The typical dosage regimen for Vomiren 0.5 mg varies depending on the indication and age of the patient:

Adult Tablet Dosage: For general adult use, the recommended dosage is 0.5 mg taken orally once daily.

Adult IV Dosage: For intravenous administration in adults:

• A single IV dose of 0.075 mg should be administered over 10 seconds for general use.
• For chemotherapy-induced nausea and vomiting, a single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before the start of chemotherapy.
• For radiotherapy-induced nausea and vomiting, a single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before each week of radiation fraction.
• For post-operative nausea and vomiting, a single IV dose of 0.075 mg should be administered over 10 seconds immediately before induction of anesthesia.

Children Dosage: For pediatric patients aged 1 month to 17 years, the dosage for IV administration is based on body weight:

• A single IV dose at 20 mcg/kg body weight, with a maximum dose of 1.5 mg.

Interaction

In clinical trials, Vomiren 0.5 mg injection has been safely combined with various medications, including corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, and anticholinergic agents. It's noteworthy that Vomiren 0.5 mg did not interfere with the anticancer activity of drugs such as cisplatin, cyclophosphamide, cytarabine, doxorubicin, and mitomycin C in murine tumor models.

Moreover, when administered concurrently with metoclopramide, Vomiren 0.5 mg showed no significant pharmacokinetic interactions. In vitro studies further support the safety profile of Vomiren 0.5 mg, indicating that it does not inhibit the activity of various cytochrome P450 enzymes, including CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4/5. Additionally, it does not induce the activity of CYP1A2, CYP2D6, or CYP3A4/5. As a result, the likelihood of clinically significant drug interactions with Vomiren 0.5 mg appears to be low.

These findings provide reassurance regarding the safety and compatibility of Vomiren 0.5 mg with other medications commonly used in clinical practice, particularly in patients requiring concurrent treatment for various conditions. However, as with any medication, it's essential to consult healthcare professionals regarding potential drug interactions before initiating therapy.

Contraindications

Vomiren 0.5 mg is contraindicated in patients known to have hypersensitivity to the drug or any of its components.

Pregnancy & Lactation

US FDA Pregnancy category B. It is not known whether Paloxiron is excreted in human milk

Precautions & Warnings

Patients with intestinal obstruction or ileus should avoid using this medication. Rapid injection may cause temporary visual changes such as blurred vision. Individuals with prolonged QT intervals should exercise caution when using this medication. Safety and efficacy have not been established in children under 18 years of age. Patients who perform skilled tasks, such as driving, should be advised that their abilities may be impaired. For lactating individuals, the effects on nursing infants are unknown; therefore, it is recommended to discontinue the drug or refrain from nursing while using it.

Storage Conditions

Keep in a dry place, away from light and heat.